Food Allergy Immunotherapy Market Report: Trends, Forecast and Competitive Analysis to 2031

Food Allergy Immunotherapy Market Trends and Forecast

The future of the global food allergy immunotherapy market looks promising with opportunities in the hospital pharmacy, online pharmacy, and retail pharmacy markets. The global food allergy immunotherapy market is expected to grow with a CAGR of 9.5% from 2025 to 2031. The major drivers for this market are the increasing awareness of food-related allergies, the rising prevalence of anaphylactic conditions, and the growing demand for personalized treatments.

• Lucintel forecasts that, within the type category, sublingual immunotherapy is expected to witness higher growth over the forecast period.

• Within the application category, retail pharmacy is expected to witness the highest growth.

• In terms of region, APAC is expected to witness the highest growth over the forecast period. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Food Allergy Immunotherapy Market

The food allergy immunotherapy market is evolving rapidly, driven by scientific breakthroughs and a deeper understanding of immune mechanisms. These emerging trends promise to revolutionize patient care by offering more effective, safer, and personalized treatment options, moving beyond traditional allergen avoidance strategies.

• Personalized Immunotherapy Approaches: This trend focuses on tailoring immunotherapy treatments based on individual patient profiles, including their specific allergen sensitivities, genetic predispositions, and immune responses. Advanced diagnostics and biomarkers are being used to identify suitable candidates and optimize dosing, leading to higher efficacy and reduced side effects.

• Development of Biologic Therapies: Biologic drugs, such as monoclonal antibodies, are increasingly being explored and approved as adjuncts or standalone treatments in food allergy immunotherapy. These therapies target specific immune pathways involved in allergic reactions, aiming to improve safety and efficacy, especially for severe or multi-allergic patients, often used in combination with traditional immunotherapies.

• Non-Oral/Novel Delivery Methods: Beyond traditional oral immunotherapy (OIT) and subcutaneous immunotherapy (SCIT), there’s a growing interest in novel delivery methods like epicutaneous (patch-based) immunotherapy (EPIT) and sublingual immunotherapy (SLIT). These methods aim to improve patient adherence, reduce systemic reactions, and enhance convenience, making treatment more accessible and safer for a broader patient population, particularly children.

• Combination Therapies: Research is focusing on combining different immunotherapy approaches or integrating immunotherapy with other treatments, such as biologics, to enhance desensitization and achieve sustained unresponsiveness. This synergistic approach aims to overcome limitations of monotherapy, improving outcomes and expanding treatment options for complex food allergies.

• Digital Health and Remote Monitoring: The integration of digital health technologies, including mobile applications and wearable devices, for remote patient monitoring and adherence tracking is an emerging trend. These tools facilitate better communication between patients and healthcare providers, improve treatment adherence, and allow for real-time monitoring of symptoms and reactions, enhancing safety and convenience of long-term therapy. These trends are reshaping the food allergy immunotherapy market by enabling more personalized and effective treatments, expanding delivery options, and leveraging technology to enhance patient management and safety.

Recent Development in the Food Allergy Immunotherapy Market

The food allergy immunotherapy market is undergoing dynamic changes, with significant advancements aimed at improving treatment efficacy, safety, and accessibility for patients. These recent developments reflect a growing understanding of food allergies and a commitment to providing more definitive long-term solutions beyond mere allergen avoidance.

• Xolair Approval: The FDA’s recent approval of Xolair (omalizumab) for reducing allergic reactions, including anaphylaxis, in people aged 1 and older with IgE-mediated food allergies is a major breakthrough. This broadens the treatment landscape, offering a new therapeutic option for individuals with various food allergies, reducing the severity of accidental exposures.

• Expanded Indications for Oral Immunotherapy: There’s an ongoing expansion of approved oral immunotherapy (OIT) treatments, such as PALFORZIA for peanut allergy, to include broader age ranges, including toddlers. This development signifies a growing recognition of the importance of early intervention, potentially offering long-term benefits and improving quality of life for young children with food allergies.

• Advancements in Epicutaneous Immunotherapy (EPIT): Progress in epicutaneous immunotherapy, notably with patch-based systems like Viaskin Peanut, continues to be a key development. While facing regulatory hurdles, ongoing trials and positive regulatory updates indicate potential for a non-invasive, convenient, and safer alternative to oral immunotherapy, particularly appealing for pediatric patients.

• Focus on Multi-Allergen Immunotherapy: Researchers and companies are increasingly exploring and developing immunotherapy approaches that target multiple food allergens simultaneously. This development addresses the needs of patients with multiple food allergies, a common occurrence, aiming to simplify treatment regimens and provide broader protection against various triggers.

• Increased R&D in Adjunctive Therapies: There’s a surge in research and development into adjunctive therapies that can be combined with existing immunotherapies to enhance efficacy or improve safety. This includes biologics and other immunomodulators, aiming to accelerate desensitization, reduce adverse events, and enable more patients to successfully complete immunotherapy. These developments are profoundly impacting the food allergy immunotherapy market by expanding treatment options, improving safety profiles, increasing accessibility for different age groups, and fostering a more comprehensive approach to managing complex food allergies.

Strategic Growth Opportunities in the Food Allergy Immunotherapy Market

The food allergy immunotherapy market is ripe with strategic growth opportunities across various applications, driven by the persistent unmet need for effective long-term solutions and the increasing understanding of allergic disease mechanisms. Capitalizing on these opportunities is crucial for stakeholders to drive innovation and expand patient access.

• Peanut Allergy Treatment: Despite existing approved therapies, the significant prevalence and severity of peanut allergy continue to present a major growth opportunity. Developing and commercializing novel, safer, and more convenient immunotherapy options, including improved oral, sublingual, or epicutaneous formulations, or combination therapies, can capture a substantial market share.

• Multi-Allergen Desensitization: A significant portion of food-allergic individuals react to multiple allergens. Therefore, developing and offering therapies that can safely and effectively desensitize patients to multiple food allergens simultaneously represents a major growth avenue. This addresses a critical unmet need and simplifies treatment regimens for complex cases.

• Pediatric Food Allergy Management: Early intervention in food allergy is showing promising results in terms of long-term tolerance. Expanding the development and availability of immunotherapy options specifically tailored for younger children (infants and toddlers), with improved safety profiles and ease of administration, presents a substantial growth opportunity due to the high incidence in this age group.

• Development of Adjunctive Therapies: Growth opportunities lie in researching and commercializing adjunctive therapies (e.g., biologics, probiotics, prebiotics) that can enhance the efficacy, accelerate the desensitization process, or improve the safety profile of existing immunotherapies. These adjuncts could allow for faster treatment completion or enable successful therapy in more challenging cases.

• Telemedicine and Remote Patient Monitoring: Leveraging digital health platforms for remote patient monitoring, consultation, and adherence tracking in immunotherapy can significantly enhance accessibility and convenience, especially for long-term treatments. This application reduces the burden on healthcare facilities and improves patient compliance, creating a significant growth opportunity for integrated digital solutions. These opportunities are impacting the food allergy immunotherapy market by encouraging targeted research and development, broadening the scope of treatable allergies, focusing on early intervention, and embracing digital solutions to enhance patient care and accessibility.

Food Allergy Immunotherapy Market Driver and Challenges

The food allergy immunotherapy market is shaped by a complex interplay of various technological, economic, and regulatory factors. Understanding these major drivers that propel market growth and the significant challenges that impede it is crucial for stakeholders to strategize effectively and respond to the evolving landscape. The factors responsible for driving the food allergy immunotherapy market include: 1. Rising Prevalence of Food Allergies: The increasing global incidence of food allergies, particularly among children, is a primary driver. This growing patient population, coupled with the potential for severe, life-threatening reactions, fuels the demand for effective long-term treatments like immunotherapy that aim to induce tolerance. 2. Growing Awareness and Diagnosis: Enhanced awareness among the public and healthcare professionals regarding food allergies, coupled with advancements in diagnostic tools (e.g., molecular diagnostics), is leading to earlier and more accurate diagnoses. This increased identification of patients suitable for immunotherapy drives market demand. 3. Improved Efficacy and Safety Profiles: Recent advancements in immunotherapy techniques, including more refined dosing protocols, novel delivery methods (e.g., epicutaneous patches), and the integration of adjunctive therapies, are leading to improved efficacy and safety, making these treatments more appealing to both patients and clinicians. 4. Positive Regulatory Environment: Regulatory bodies in key markets are increasingly supportive of new food allergy immunotherapy approvals. Expedited review pathways and a willingness to consider novel treatments for this high unmet medical need encourage pharmaceutical companies to invest further in research and development, driving innovation. 5. Shift from Avoidance to Treatment: There is a growing paradigm shift from traditional allergen avoidance strategies to active disease-modifying treatments like immunotherapy. Patients and healthcare providers are seeking solutions that can build tolerance, reduce anxiety, and improve quality of life, thereby expanding the market for these therapies. Challenges in the food allergy immunotherapy market are: 1. High Cost of Treatment: Food allergy immunotherapy, especially newer biologic-inclusive regimens, can be very expensive, posing a significant barrier to access for many patients. The high cost affects affordability and reimbursement policies, limiting widespread adoption, particularly in healthcare systems with budget constraints. 2. Long Treatment Duration: Immunotherapy protocols often require a long treatment duration, spanning several months to years, which can lead to issues with patient adherence. Maintaining consistent treatment over such extended periods is challenging for patients and requires significant commitment, impacting overall treatment success rates. 3. Risk of Adverse Reactions: While generally safe, immunotherapy carries a risk of adverse reactions, ranging from mild local symptoms to systemic reactions, including anaphylaxis. This necessitates careful medical supervision, especially during dose escalation phases, and can be a deterrent for some patients and healthcare providers, requiring robust safety protocols. The food allergy immunotherapy market is driven by the urgent need for effective treatments for a growing patient population and bolstered by scientific advancements and supportive regulatory frameworks. However, significant challenges related to treatment cost, lengthy regimens, and the inherent risk of adverse reactions must be addressed to ensure broader accessibility and sustained market growth.

List of Food Allergy Immunotherapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies food allergy immunotherapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the food allergy immunotherapy companies profiled in this report include-

• Anergis

• HAL Allergy Group

• Merck

• Stallergenes Greer

• Laboratorios LETI

Food Allergy Immunotherapy Market by Segment

The study includes a forecast for the global food allergy immunotherapy market by type, application, and region.

Food Allergy Immunotherapy Market by Type [Value from 2019 to 2031]:

• Subcutaneous Immunotherapy

• Sublingual Immunotherapy

Food Allergy Immunotherapy Market by Application [Value from 2019 to 2031]:

• Hospital Pharmacies

• Online Pharmacies

• Retail Pharmacies

• Others

Food Allergy Immunotherapy Market by Region [Value from 2019 to 2031]:

• North America

• Europe

• Asia Pacific

• The Rest of the World

Country Wise Outlook for the Food Allergy Immunotherapy Market

The food allergy immunotherapy market is experiencing significant growth, driven by the increasing prevalence of food allergies globally and a shift towards more targeted and disease-modifying treatments. Recent advancements in oral, sublingual, and epicutaneous immunotherapies are offering new hope for patients seeking to build tolerance and reduce the risk of severe reactions.

• United States: The U.S. market has seen significant developments, including the FDA approval of omalizumab for IgE-mediated food allergies to reduce allergic reactions, including anaphylaxis. This, alongside the continued use and expansion of peanut oral immunotherapy (PALFORZIA) for broader age groups, highlights a strong focus on new therapeutic options and regulatory support.

• China: China’s food allergy immunotherapy market is projected for rapid growth. While specific immunotherapy treatments are still gaining traction, there’s a rising awareness of food allergies, particularly in children, driving demand for advanced diagnostic tools and treatment options, including a growing interest in personalized medicine approaches.

• Germany: Germany is a significant market, particularly for pollen allergies, which often correlate with food allergies. Recent developments include the launch of sublingual allergy immunotherapy tablets for various allergens. The focus is on increasing accessibility and convenience of home-use treatments, reflecting a strong patient base for allergy care.

• India: India’s market is witnessing increased awareness and education regarding food allergies, leading to higher demand for allergen-free products and diagnostic services. Immunotherapy is gaining popularity as a long-term treatment option, with a growing emphasis on personalized medicine and technological advancements in allergy diagnosis, such as AI-driven tests.

• Japan: Japan’s food allergy diagnosis and treatment market is seeing notable growth due to increasing prevalence and proactive government policies regarding food allergen labeling. Immunotherapy is gaining traction as a long-term solution, with a focus on developing innovative treatment options and educational programs for patients and families.

Features of the Global Food Allergy Immunotherapy Market

Market Size Estimates: Food allergy immunotherapy market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions. Segmentation Analysis: Food allergy immunotherapy market size by type, application, and region in terms of value ($B). Regional Analysis: Food allergy immunotherapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the food allergy immunotherapy market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the food allergy immunotherapy market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the growth forecast for food allergy immunotherapy market? Answer: The global food allergy immunotherapy market is expected to grow with a CAGR of 9.5% from 2025 to 2031. Q2. What are the major drivers influencing the growth of the food allergy immunotherapy market? Answer: The major drivers for this market are the increasing awareness of food-related allergies, the rising prevalence of anaphylactic conditions, and the growing demand for personalized treatments. Q3. What are the major segments for food allergy immunotherapy market? Answer: The future of the food allergy immunotherapy market looks promising with opportunities in the hospital pharmacy, online pharmacy, and retail pharmacy markets. Q4. Who are the key food allergy immunotherapy market companies? Answer: Some of the key food allergy immunotherapy companies are as follows:

• Anergis

• HAL Allergy Group

• Merck

• Stallergenes Greer

• Laboratorios LETI Q5. Which food allergy immunotherapy market segment will be the largest in future? Answer: Lucintel forecasts that, within the type category, sublingual immunotherapy is expected to witness higher growth over the forecast period. Q6. In food allergy immunotherapy market, which region is expected to be the largest in next 5 years? Answer: In terms of region, APAC is expected to witness the highest growth over the forecast period. Q7. Do we receive customization in this report? Answer: Yes, Lucintel provides 10% customization without any additional cost.